KIF22 promotes bladder cancer progression by activating the expression of CDCA3 Retraction in /10.3892/ijmm.2023.5295

Li,Kai; Li,Song; Tang,Shuai; Zhang,Minghao; Ma,Zhen; Wang,Qi; Chen,Fangmin

doi:10.3892/ijmm.2021.5044

KIF22 promotes bladder cancer progression by activating the expression of CDCA3

Retraction in: /10.3892/ijmm.2023.5295

Authors:
- Kai Li
- Song Li
- Shuai Tang
- Minghao Zhang
- Zhen Ma
- Qi Wang
- Fangmin Chen
View Affiliations

Affiliations: Department of Urology, Tianjin Third Central Hospital Affiliated to Nankai University, Tianjin 300170, P.R. China
Published online on: October 7, 2021 https://doi.org/10.3892/ijmm.2021.5044
Article Number: 211
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer is a common malignant tumor of the urinary system and is associated with a high morbidity and mortality, due to the difficulty in the accurate diagnosis of patients with early‑stage bladder cancer and the lack of effective treatments for patients with advanced bladder cancer. Thus, novel therapeutic targets are urgently required for this disease. Kinesin family member 22 (KIF22) is a kinesin‑like DNA binding protein belonging to kinesin family, and is involved in the regulation of mitosis. KIF22 has also been reported to promote the progression of several types of cancer, such as breast cancer and melanoma. The present study demonstrates the high expression of KIF22 in human bladder cancer tissues. KIF22 was found to be associated with clinical features, including clinical stage (P=0.003) and recurrence (P=0.016), and to be associated with the prognosis of patients with bladder cancer. Furthermore, it was found that KIF22 silencing inhibited the proliferation of bladder cancer cells in vitro and tumor progression in mice. Additionally, it was noted that KIF22 transcriptionally activated cell division cycle‑associated protein 3 expression, which was also confirmed in tumors in mice. Taken together, the present study investigated the molecular mechanisms underlying the promotion of bladder cancer by KIF22 and provide a novel therapeutic target for the treatment of bladder cancer.
Introduction

View Figures

View References

1	Franekova M, Halasova E, Bukovska E, Luptak J and Dobrota D: Gene polymorphisms in bladder cancer. Urol Oncol. 26:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
2	Kochańska-Dziurowicz AA, Mielniczuk MJ, Bijak A and Palugniok R: Estimation of usefulness of monitoring tissue polypeptide antigen-TPA-M concentrations in the effectiveness surgical treatment of urinary bladder cancer. Nucl Med Rev Cent East Eur. 5:109–111. 2002.
3	McLellan RA, French CG and Bell DG: Trends in the incidence of bladder cancer in Nova Scotia: A twenty-year perspective. Can J Urol. 10:1880–1884. 2003.PubMed/NCBI
4	Dalbagni G: The management of superficial bladder cancer. Nat Clin Pract Urol. 4:254–260. 2007. View Article : Google Scholar : PubMed/NCBI
5	Kiyoshima K, Akitake M, Shiota M, Takeuchi A, Takahashi R, Inokuchi J, Tatsugami K, Yokomizo A and Eto M: Prognostic significance of preoperative urine cytology in low-grade non-muscleinvasive bladder cancer. Anticancer Res. 36:799–802. 2016.PubMed/NCBI
6	Lavery HJ, Zaharieva B, McFaddin A, Heerema N and Pohar KS: A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection. BMC Cancer. 17:2472017. View Article : Google Scholar : PubMed/NCBI
7	Ikushima H, Iwamoto S, Osaki K, Furutani S, Yamashita K, Kawanaka T, Kubo A, Takegawa Y, Kudoh T, Kanayama H and Nishitani H: Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer. Radiat Med. 26:156–163. 2008. View Article : Google Scholar : PubMed/NCBI
8	Black PC, Agarwal PK and Dinney CP: Targeted therapies in bladder cancer-an update. Urol Oncol. 25:433–438. 2007. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Yang X, Su LJ and Flaig TW: VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep. 24:1019–1028. 2010.PubMed/NCBI
10	Huang Z, Zhang M, Chen G, Wang W, Zhang P, Yue Y, Guan Z, Wang X and Fan J: Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. Int J Oncol. 54:1555–1566. 2019.PubMed/NCBI
11	Miki T, Nishina M and Goshima G: RNAi screening identifies the armadillo repeat-containing kinesins responsible for microtubule-dependent nuclear positioning in Physcomitrella patens. Plant Cell Physiol. 56:737–749. 2015. View Article : Google Scholar : PubMed/NCBI
12	Gould R, Freund C, Palmer F, Knapp PE, Huang J, Morrison H and Feinstein DL: Messenger RNAs for kinesins and dynein are located in neural processes. Biol Bull. 197:259–260. 1999. View Article : Google Scholar : PubMed/NCBI
13	Hu Z, Liang Y, Meng D, Wang L and Pan J: Microtubule depolymerizing kinesins in the regulation of assembly, disassembly, and length of cilia and flagella. Int Rev Cell Mol Biol. 317:241–265. 2015. View Article : Google Scholar
14	Vicente JJ and Wordeman L: Mitosis, microtubule dynamics and the evolution of kinesins. Exp Cell Res. 334:61–69. 2015. View Article : Google Scholar : PubMed/NCBI
15	Min BJ, Kim N, Chung T, Kim OH, Nishimura G, Chung CY, Song HR, Kim HW, Lee HR, Kim J, et al: Whole-exome sequencing identifies mutations of KIF22 in spondyloepimetaphyseal dysplasia with joint laxity, leptodactylic type. Am J Hum Genet. 89:760–766. 2011. View Article : Google Scholar : PubMed/NCBI
16	Park SM, Littleton JT, Park HR and Lee JH: Drosophila homolog of human KIF22 at the autism-linked 16p112 loci influences synaptic connectivity at larval neuromuscular junctions. Exp Neurobiol. 25:33–39. 2016. View Article : Google Scholar : PubMed/NCBI
17	Bruzzoni-Giovanelli H, Fernandez P, Veiga L, Podgorniak MP, Powell DJ, Candeias MM, Mourah S, Calvo F and Marín M: Distinct expression patterns of the E3 ligase SIAH-1 and its partner Kid/KIF22 in normal tissues and in the breast tumoral processes. J Exp Clin Cancer Res. 29:102010. View Article : Google Scholar : PubMed/NCBI
18	Yu Y, Wang XY, Sun L, Wang YL, Wan YF, Li XQ and Feng YM: Inhibition of KIF22 suppresses cancer cell proliferation by delaying mitotic exit through upregulating CDC25C expression. Carcinogenesis. 35:1416–1425. 2014. View Article : Google Scholar : PubMed/NCBI
19	Manning CS, Hooper S and Sahai EA: Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells. Oncogene. 34:4320–4332. 2015. View Article : Google Scholar :
20	Pike R, Ortiz-Zapater E, Lumicisi B, Santis G and Parsons M: KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation. Sci Signal. 11:eaaq10602018. View Article : Google Scholar : PubMed/NCBI
21	Ayad NG, Rankin S, Murakami M, Jebanathirajah J, Gygi S and Kirschner MW: Tome-1, a trigger of mitotic entry, is degraded during G1 via the APC. Cell. 113:101–113. 2003. View Article : Google Scholar : PubMed/NCBI
22	Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, Hooper JD, Richard DJ and O'Byrne KJ: Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer. J Thorac Oncol. 12:1071–1084. 2017. View Article : Google Scholar : PubMed/NCBI
23	Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Bukawa H: Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer. 12:3212012. View Article : Google Scholar : PubMed/NCBI
24	Chen J, Zhu S, Jiang N, Shang Z, Quan C and Niu Y: HoxB3 promotes prostate cancer cell progression by transactivating CDCA3. Cancer Lett. 330:217–224. 2013. View Article : Google Scholar
25	Hu Q, Fu J, Luo B, Huang M, Guo W, Lin Y, Xie X and Xiao S: OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG, CD9, CCND2 and CDCA3: A bioinformatic analysis combine with RNAi and oligonucleotide microarray. Oncol Rep. 33:1965–1975. 2015. View Article : Google Scholar : PubMed/NCBI
26	Li B, Zhu FC, Yu SX, Liu SJ and Li BY: Suppression of KIF22 inhibits cell proliferation and xenograft tumor growth in colon cancer. Cancer Biother Radiopharm. 35:50–57. 2020. View Article : Google Scholar
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
28	Zhao Y, Zhao Z, Cui Y, Chen X, Chen C, Xie C, Qin B and Yang Y: Redox-responsive glycosylated combretastatin A-4 derivative as novel tubulin polymerization inhibitor for glioma and drug delivery. Drug Develop Res. Sep 29–2021.Epub ahead of print. View Article : Google Scholar
29	Obermann EC, Meyer S, Hellge D, Zaak D, Filbeck T, Stoehr R, Hofstaedter F, Hartmann A and Knuechel R: Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. Oncol Rep. 11:745–751. 2004.PubMed/NCBI
30	van Kessel KE, Zuiverloon TC, Alberts AR, Boormans JL and Zwarthoff EC: Targeted therapies in bladder cancer: An overview of in vivo research. Nat Rev Urol. 12:681–694. 2015. View Article : Google Scholar : PubMed/NCBI
31	Hautmann RE, Abol-Enein H, Davidsson T, Gudjonsson S, Hautmann SH, Holm HV, Lee CT, Liedberg F, Madersbacher S, Manoharan M, et al: ICUD-EAU international consultation on bladder cancer 2012: Urinary diversion. Eur Urol. 63:67–80. 2013. View Article : Google Scholar
32	Liu J, Zhang Y, Yu C, Zhang P, Gu S, Wang G, Xiao H and Li S: Bergenin inhibits bladder cancer progression via activating the PPARγ/PTEN/Akt signal pathway. Drug Dev Res. 82:278–286. 2021. View Article : Google Scholar
33	Li Y, Lu W, Chen D, Boohaker RJ, Zhai L, Padmalayam I, Wennerberg K, Xu B and Zhang W: KIFC1 is a novel potential therapeutic target for breast cancer. Cancer Biol Ther. 16:1316–1322. 2015. View Article : Google Scholar : PubMed/NCBI
34	Wang J, Ma S, Ma R, Qu X, Liu W, Lv C, Zhao S and Gong Y: KIF2A silencing inhibits the proliferation and migration of breast cancer cells and correlates with unfavorable prognosis in breast cancer. BMC Cancer. 14:4612014. View Article : Google Scholar : PubMed/NCBI
35	Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z, et al: Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci. 59:795–806. 2014. View Article : Google Scholar :
36	Xu H, Choe C, Shin SH, Park SW, Kim HS, Jung SH, Yim SH, Kim TM and Chung YJ: Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma. Exp Mol Med. 46:e972014. View Article : Google Scholar : PubMed/NCBI
37	Chen S, Han M, Chen W, He Y, Huang B, Zhao P, Huang Q, Gao L, Qu X and Li X: KIF1B promotes glioma migration and invasion via cell surface localization of MT1-MMP. Oncol Rep. 35:971–977. 2016. View Article : Google Scholar
38	Thériault BL, Basavarajappa HD, Lim H, Pajovic S, Gallie BL and Corson TW: Transcriptional and epigenetic regulation of KIF14 overexpression in ovarian cancer. PLoS One. 9:e915402014. View Article : Google Scholar : PubMed/NCBI
39	Zhang C, Zhu C, Chen H, Li L, Guo L, Jiang W and Lu SH: Kif18A is involved in human breast carcinogenesis. Carcinogenesis. 31:1676–1684. 2010. View Article : Google Scholar : PubMed/NCBI
40	Maddika S, Sy SM and Chen J: Functional interaction between Chfr and Kif22 controls genomic stability. J Biol Chem. 284:12998–13003. 2009. View Article : Google Scholar : PubMed/NCBI